Terremoto Biosciences, a pioneering biotechnology company at the forefront of developing novel therapeutics targeting the PI3K/AKT pathway, announced today the…
Read More
Regeneron Pharmaceuticals and Telix Pharmaceuticals Forge Strategic Alliance to Advance Precision Oncology Through Radiopharmaceutical Innovation
Regeneron Pharmaceuticals and Telix Pharmaceuticals have announced a significant partnership aimed at accelerating the development and commercialization of novel radiopharmaceutical…
Read More
Sidewinder Therapeutics Secures $137 Million in Series B Financing to Advance Bispecific Antibody-Drug Conjugate Pipeline
Sidewinder Therapeutics has announced the successful closure of a substantial $137 million Series B financing round, a significant development signaling…
Read More
Indiana University School of Medicine Scientists Develop Breakthrough Imaging Technique for Bone Marrow Analysis to Advance Disease Treatment
The landscape of hematological research and regenerative medicine has undergone a significant transformation following a major technological breakthrough by researchers…
Read More
University of Basel Researchers Replicate Human Bone Marrow in Landmark Study to Advance Blood Cancer Research and Reduce Animal Testing
In a significant breakthrough for regenerative medicine and oncology, researchers at the University of Basel and University Hospital Basel have…
Read More
Cognito Therapeutics and Ochsner Health Forge Landmark Partnership to Advance Brain Health Innovation in the Gulf South
A groundbreaking collaboration has been established between US-based neurotechnology firm Cognito Therapeutics and Ochsner Health, a leading integrated healthcare system…
Read More
Washington University Researchers Develop p-tau217 Blood Test Clock Capable of Predicting Alzheimer’s Symptom Onset Years in Advance
In a significant advancement for neurodegenerative disease research, scientists at Washington University School of Medicine in St. Louis have pioneered…
Read More
Congruence secures $39.5m to advance small molecule correctors pipeline
Congruence Therapeutics, a pioneering biotechnology company focused on developing novel small molecule correctors, has successfully closed a significant $39.5 million…
Read More
Eli Lilly’s Triple Agonist Achieves 16.8% Weight Loss in Phase 3 Trial for Type 2 Diabetes, Signaling Major Therapeutic Advance
Eli Lilly and Company today announced groundbreaking results from a Phase 3 clinical trial for its investigational triple agonist, retatrutide,…
Read More
Excalipoint Therapeutics Launches with $68.7 Million Seed Funding to Advance Novel T-Cell Engager Pipeline
Chinese biotech startup Excalipoint Therapeutics has officially launched with a substantial $68.7 million in seed funding, positioning itself to accelerate…
Read MoreYOU MAY HAVE MISSED
